5月27日，宝济药业-B盘中上涨5.05%，报26.24港元/股，成交额8176.22万港元。
消息面上，公司于5月26日公告，刘彦君博士获委任为第二届董事会董事长，任期三年。此外，近期公司核心管线注射用KJ103拟纳入优先审评，该产品为全球首创的重组IgG降解酶，适用于高度致敏肾移植患者脱敏治疗。此前公司股价自4月底闪崩暴跌65%后持续低位运行，控股股东已表态拟增持股份，新管理层架构确立叠加研发管线推进，市场情绪有所修复。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.